Loading clinical trials...
Loading clinical trials...
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Wenjin Yin
NCT07586215 · Breast Cancer Metastatic
NCT05831878 · Advanced Breast Cancer
NCT07578064 · Breast Cancer, Bone Marrow Suppression
NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more
NCT07368998 · Breast Cancer
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions